Bioequivalence Study of Canagliflozin 300 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Canagliflozin 300 mg film-coated tablets in healthy participants under fasting conditions. This assessment is clinically relevant as it determines whether the generic formulation of Canagliflozin is therapeutically equivalent to the reference product, ensuring similar efficacy and safety profiles. No secondary objectives are specified for this study.

The clinical trial involves a study population that includes both **male** and **female** participants. The age range of the participants is categorized as **adults**, although specific age limits are not provided. The trial population is noted to include a **vulnerable population**, but further details on the nature of this vulnerability are not specified. The sponsor has not provided information regarding the total number of participants involved in the study. Participants are not required to have any specific medical condition, as the trial is open to individuals without any pre-existing medical conditions. Lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data. The selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the **bioequivalence** of Canagliflozin 300 mg film-coated tablets in healthy participants under fasting conditions. This study is a Phase 2 trial, which is randomized, double-blind, and controlled to ensure the reliability and validity of the results. The trial is expected to commence recruitment on July 8, 2025, and conclude by November 14, 2025, with the overall duration of the trial spanning approximately four months.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit. During this visit, eligibility criteria will be assessed to ensure participants meet the necessary requirements for inclusion in the study. Following successful screening, participants will be randomized into different study arms. Subsequent follow-up visits will be scheduled to monitor the participants' health status, adherence to the study protocol, and to collect necessary data for the trial's objectives. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the bioequivalence of the investigational product.

The expected length of participant involvement in the study is approximately four months, aligning with the overall trial duration. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent by the participant. The study is conducted under strict ethical guidelines to ensure the safety and well-being of all participants throughout the trial period.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on July 8, 2025, with an estimated completion date of November 14, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The focus will be on evaluating the treatment's impact over the course of the study, adhering to the protocols typical of Phase 2 trials. The trial's design will ensure that efficacy is assessed in a manner consistent with clinical research standards, although specific tools or instruments for efficacy assessment are not specified in the provided information.